Telo Genomics Corp Stock Revenue
| TDSGF Stock | USD 0.08 0.0007 0.87% |
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo OTC Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics otc stock.
Telo |
Telo Genomics Corp OTC Stock Revenue Analysis
Telo Genomics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Telo Genomics Corp reported 0.0 of revenue. This is 100.0% lower than that of the Health Care Technology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Telo Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in revenue category among its peers.
Telo Fundamentals
| Return On Equity | -0.78 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 13.73 M | |||
| Shares Outstanding | 59.42 M | |||
| Shares Owned By Insiders | 6.52 % | |||
| Shares Owned By Institutions | 1.83 % | |||
| Price To Earning | (0.67) X | |||
| Price To Book | 10.46 X | |||
| EBITDA | (2.05 M) | |||
| Net Income | (2.11 M) | |||
| Cash And Equivalents | 2.69 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 40 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 14.66 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.87 | |||
| Market Capitalization | 12.81 M | |||
| Total Asset | 2.83 M | |||
| Net Asset | 2.83 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo OTC Stock
Telo Genomics financial ratios help investors to determine whether Telo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.